首页> 美国卫生研究院文献>Scientific Reports >Deep sequencing analysis of the heterogeneity of seed and commercial lots of the bacillus Calmette-Guérin (BCG) tuberculosis vaccine substrain Tokyo-172
【2h】

Deep sequencing analysis of the heterogeneity of seed and commercial lots of the bacillus Calmette-Guérin (BCG) tuberculosis vaccine substrain Tokyo-172

机译:对卡介苗(BCG)结核菌疫苗Tokyo-172的种子和商业批次异质性的深度测序分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BCG, only vaccine available to prevent tuberculosis, was established in the early 20th century by prolonged passaging of a virulent clinical strain of Mycobacterium bovis. BCG Tokyo-172, originally distributed within Japan in 1924, is one of the currently used reference substrains for the vaccine. Recently, this substrain was reported to contain two spontaneously arising, heterogeneous subpopulations (Types I and II). The proportions of the subpopulations changed over time in both distributed seed lots and commercial lots. To maintain the homogeneity of live vaccines, such variations and subpopulational mutations in lots should be restrained and monitored. We incorporated deep sequencing techniques to validate such heterogeneity in lots of the BCG Tokyo-172 substrain without cloning. By bioinformatics analysis, we not only detected the two subpopulations but also detected two intrinsic variations within these populations. The intrinsic variants could be isolated from respective lots as colonies cultured on plate media, suggesting analyses incorporating deep sequencing techniques are powerful, valid tools to detect mutations in live bacterial vaccine lots. Our data showed that spontaneous mutations in BCG vaccines could be easily monitored by deep sequencing without direct isolation of variants, revealing the complex heterogeneity of BCG Tokyo-172 and its daughter lots currently in use.
机译:BCG是唯一可用于预防结核病的疫苗,它是在20世纪初通过长时间传播有毒的牛分枝杆菌临床菌株而建立的。 BCG Tokyo-172最初于1924年在日本发行,是该疫苗目前使用的参考亚菌株之一。最近,据报道该亚菌株包含两个自发的异质亚群(I型和II型)。分配的种子批次和商业批次中亚种群的比例均随时间变化。为了保持活疫苗的同质性,应限制和监测批次中的此类变异和亚种群突变。我们采用了深度测序技术来验证许多BCG Tokyo-172亚株中的这种异质性而无需克隆。通过生物信息学分析,我们不仅检测了这两个亚群,而且还检测了这些种群中的两个内在变异。当在平板培养基上培养菌落时,可以从各个批次中分离出固有变异体,这表明结合深度测序技术的分析是检测活细菌疫苗批次中突变的有力且有效工具。我们的数据表明,无需深度分离即可通过深度测序轻松监测BCG疫苗中的自发突变,从而揭示了BCG Tokyo-172及其目前使用的子代批次的复杂异质性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号